Anti-Mouse CD223 (LAG-3) – Purified (PhenoCyler-Fusion (CODEX)® Ready)
Anti-Mouse CD223 (LAG-3) – Purified (PhenoCyler-Fusion (CODEX)® Ready)
Product No.: L502
- -
- -
Clone C9B7W Target CD223 Formats AvailableView All Product Type Monoclonal Antibody Isotype IgG1 Applications IHC FF , PhenoCycler® |
- -
- -
CODEX® DetailsValidation Notes Clone C9B7W has been validated for use on CODEX® using mouse T-cell Sarcoma fresh frozen (FF) tissue. Tissue Screened T-cell Sarcoma Tissue Preparation FF (Fresh Frozen) Antibody and Reporter DetailsReactivity Species Mouse Host Species Rat Concentration 0.5 mg/ml Immunogen Purified Recombinant Mouse LAG-3 Formulation This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4. Storage and Handling This antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. Applications and Recommended Usage? Quality Tested by Leinco CODEX® This CD223/LAG-3 (Clone C9B7W) antibody is formulated to simplify the antibody preparation needed when performing a CODEX® barcode conjugate. The suggested concentration is 0.5 mg/ml. RRID AB_2892932 Country of Origin USA Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionSpecificity Clone C9B7W recognizes and specifically binds to an epitope in the D2 domain of CD223. Antigen Distribution CD223 is expressed on T regulatory cells, activated T cells and NK cells. Background LAG-3 is a 70-kD, type-I transmembrane glycoprotein within the Ig superfamily with four extracellular Ig-like domains (D1 to D4) and is structurally homologous to CD4. LAG-3 is a cell surface molecule with various biologic effects on T cell function. It has been reported to be involved in Treg suppressive function. It negatively regulates cellular proliferation, activation, and homeostasis of T cells, in a similar manner to CTLA-4 and PD-1. Human LAG-3 is approximately 70% homologous with murine LAG3, and it binds MHC class II molecules with higher affinity than CD4. As an immune checkpoint receptor, LAG-3 is the target of various drug development programs seeking to expand treatments for cancer and autoimmune disorders. In its soluble form, LAG-3 is being developed as a cancer drug. As an antagonist, LAG-3 antibody can activate T effector cells via the downregulation of the LAG-3 inhibiting signal into pre-activated LAG-3+ cells. In addition, it can inhibit antigen-specific Treg suppressive activity. As an agonist antibody, it can be used to diminish an autoimmune response and is currently being investigated for the treatment of plaque psoriasis. Antigen DetailsProtein PubMed NCBI Gene Bank ID Technical Protocols |
Related Products
Formats Available
- -
- -
Prod No. | Description |
---|---|
C2252 | |
C2253 | |
C2254 | |
C2255 | |
C2256 | |
C2249 | |
C2251 | |
C2250 | |
L306 | |
C2155 | |
L502 | |
C2852 | |
L313 | |
L310 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.